Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer.

ABSTRACT:

Background

Breast cancer is the most common cancer in women diagnosed in the U.S. and worldwide. Obesity increases breast cancer risk without clear underlying molecular mechanisms. Our studies demonstrate that circulating adipose fatty acid binding protein (A-FABP, or FABP4) links obesity-induced dysregulated lipid metabolism and breast cancer risk, thus potentially offering a new target for breast cancer treatment.

Methods

We immunized FABP4 knockout mice with recombinant human FABP4 and screened hybridoma clones with specific binding to FABP4. The potential effects of antibodies on breast cancer cells in vitro were evaluated using migration, invasion, and limiting dilution assays. Tumor progression in vivo was evaluated in various types of tumorigenesis models including C5

SUBMITTER: Hao J 

PROVIDER: S-EPMC11270797 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature